REVELATION BIOSCIENCES INC (REVB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.010.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · REVB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
REVB — earnings miss
Dated 2026-08-06
and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
Why it matters: Starting enrollment is important for the Gemini treatment. It could create market chances.
Supportive ifEnrollment will start by the end of 2026, according to management.
Worry ifEnrollment does not start by year-end 2026.
Why it matters: Another earnings miss would confirm ongoing struggles and could lead to further declines in stock price.
Worry ifQ2 earnings report did not meet analyst expectations.
Less concerning ifQ2 earnings report was better than what analysts expected.
Why it matters: Starting enrollment is key for the Gemini study on acute kidney injury. This may help shareholders.
Supportive ifEnrollment will start by the end of 2026, according to management.
Worry ifEnrollment is delayed beyond year-end 2026.
Why it matters: Updates on capital use show what management plans for growth.
Watch forManagement shares a new plan for how to use capital.
Also watch forNo updates or a poor outlook on capital use.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$192 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $874 loss on $10,000 · 8.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,172 loss on $10,000 · 91.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: High operating losses show poor cash flow management. This may hurt investor trust.
Worry ifQ2 operating loss reported worse than $3 million.
Less concerning ifQ2 operating loss was better than $3 million.
Why it matters: Higher cash burn may show financial trouble. This can affect how long operations last.
Worry ifNet cash used for operations stays at or below $3.2 million.
Less concerning ifNet cash used for operations is more than $3.2 million.